Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CCXI $5.18 0.7600 +17.19%
STML $7.79 1.0001 +14.73%
PVCT $0.38 0.0349 +9.97%
OMED $14.52 0.9400 +6.92%
VICL $4.06 0.2600 +6.84%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

VRML $1.23 -0.0700 -5.38%
MACK $6.21 -0.3300 -5.05%
FBIO $2.76 -0.1150 -4.01%
TKMR $4.09 -0.1700 -3.99%
CBMG $14.37 -0.4600 -3.10%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Bayer to Showcase Latest Oncology Research at ASCO 2016

(Yahoo! Finance) May 18, 2016 - Scientific presence features latest data on radium-223 dichloride, regorafenib, sorafenib, and pipeline research as well as findings from largest global survey in advanced prostate cancer.
read article 



AstraZeneca Highlights Continued Progress Of Oncology Pipeline At ASCO 2016

(AstraZeneca) May 19, 2016 - AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive investigational oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2016.
read corporate press release 



Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients

(Yahoo! Finance) May 18, 2016 - New analysis from phase 3 trial of Kyprolis® (carfilzomib) combination treatment in relapsed multiple myeloma patients with early disease progression; phase 1/3 MASTERKEY-265 study abstracts present data on IMLYGIC® (Talimogene Laherparepvec) in combination with pembrolizumab in patients with unresected stage IIIB-IV melanoma.
read article 



Novartis to Present Pivotal Data In Hematologic And Solid Tumor Cancers At 2016 ASCO Annual Meeting

(MarketWatch) May 18, 2016 - First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna® both in front-line and second-line following Gleevec®; first genomic analysis and 3-year efficacy/safety update for Tafinlar® + Mekinist® combination in BRAF V600E/K-mutant advanced melanoma, one of the most mature overall survival follow ups to date; data from open-label Phase II trial of investigational Tafinlar® and Mekinist® combination in previously-treated BRAF V600E-mutant advanced NSCLC.
read article 



Merck KGaA, Darmstadt, Germany, and Pfizer To Present Avelumab Data In Seven Different Cancers At ASCO Annual Meeting

(Pfizer) May 18, 2016 - 14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer; two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced mesothelioma; data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers; JAVELIN clinical program rapidly accelerating.
read corporate press release 



Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

(Pfizer) May 18, 2016 - Pfizer Inc. today announced that the company will have its largest presence to date at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7, with more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle numerous cancers and mechanisms of action.
read corporate press release 



Phase III Study of Genentech’s Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People With a Specific Type of Lung Cancer

(Genentech) May 18, 2016 - First investigational head-to-head study of Alecensa versus crizotinib in people with advanced ALK-positive non-small cell lung cancer (NSCLC).
read corporate press release 



Two-Year Overall Survival Data From Two Pivotal Opdivo (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer

(BMS) May 18, 2016 - Bristol-Myers Squibb Company announced today two-year overall survival data from two pivotal Phase 3 studies evaluating Opdivo (nivolumab) versus docetaxel in previously treated metastatic non-small cell lung cancer (NSCLC).
read corporate press release 



New KEYTRUDA® (pembrolizumab) Data From KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting

(StreetInsider) May 18, 2016 - Merck, known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of response data and three-year OS data with KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with unresectable or metastatic melanoma.
read article 



Pfizer's Ibrance Delays Breast Cancer Progression: Study

(Fox News/Reuters) May 19, 2016 - Pfizer Inc's Ibrance in combination with another commonly-used drug kept advanced breast cancer in check significantly longer than the standard treatment alone in a late stage study, according to data released on Wednesday.
read article 



Pfizer Cancer Drug Shows Promise In Combo With Merck's Keytruda

(Reuters) May 18, 2016 - An experimental Pfizer drug that helps the immune system fight cancer showed early promise against a variety of cancers when used with Merck & Co's immunotherapy Keytruda in a small clinical trial, according to data released on Wednesday.
read article 



Transplant Still Best Up-front Option in Myeloma

(Medscape Medical News) May 19, 2016 - With new therapies for multiple myeloma getting ever better, is transplant still necessary? For now, it seems the answer is yes.
read article (free registration required) 



Early Palliative Care Provides Important Benefits for Family Caregivers of Patients With Cancer

(ASCO) May 18, 2016 - A randomized clinical trial found that introducing palliative care shortly after a cancer diagnosis results in better quality of life and fewer depression symptoms for family caregivers. According to the authors, the study is the first to show that early palliative care alone for a patient with cancer can have a strong impact on family caregivers.
read press release 



PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma

(ASCO) May 18, 2016 – Long-term follow-up from a phase 1b trial (KEYNOTE-001) in newly diagnosed and previously treated patients with advanced melanoma, showed that 40% of patients were alive three years after starting pembrolizumab, with similar 36-month overall survival rates in both groups.
read press release 



Precision Medicine Yields Better Outcomes for Patients in Phase I Clinical Trials

(ASCO) May 18, 2016 – A meta-analysis of 346 phase I clinical trials involving more than 13,000 patients found that patients whose treatment was selected based on the molecular characteristics of their tumor had significantly better outcomes.
read press release 



Better Survival for Colon Cancer Patients with Left-Sided Tumors

(UCSF) May 18, 2016 - Location matters, says study to be presented at major cancer meeting.
read article 



Precision Medicine Approach To Cancer Improves On Older Methods: Study

(Reuters) May 18, 2016 - Precision medicine, or the practice of targeting biological markers on a patient's tumors, proved significantly more effective at shrinking tumors and stalling the progression of cancer in the first large-scale analysis of such treatments.
read article 



Immune Drug for Deadly Skin Cancer Shows Long-Term Survival

(CBS News/Associated Press) May 19, 2016 - A new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years, a study shows. It's a remarkable advance for patients who until recently faced dismal chances of living for more than a few months.
read article 



Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma

(Genmab) May 18, 2016 - Genmab A/S announced today that the Phase III POLLUX study (MMY3003) of daratumumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma met the primary endpoint of improving progression free survival (PFS) at a pre-planned interim analysis (Hazard Ratio (HR) = 0.37 (95% CI 0.27-0.52), p < 0.0001).
read corporate press release 



German Merck, Pfizer Immunotherapy Shows Promise In Rare Skin Cancer

(Reuters) May 18, 2016 - Germany's Merck KGaA on Wednesday reported encouraging interim data against a rare and aggressive form of skin cancer from a mid-stage trial of its experimental drug that helps the immune system attack tumors.
read article 



Merck, Bristol Drugs Show Longer Survival for Deadly Cancers

(Reuters) May 18, 2016 - Two new drugs that help the immune system fight some of the deadliest cancers are helping patients live years longer than older treatments, according to clinical trial results that should further boost confidence in this approach to oncology.
read article 



Cancer Drug Keytruda Keeps Some Patients Alive For 3 Years

(NBCNews) May 18, 2016 - The cancer drug that former president Jimmy Carter says made his melanoma seemingly disappear has helped about 40 percent of similar patients survive for as long as three years, oncologists said Wednesday.
read article 



Cancer Drug Keytruda Keeps Some Patients Alive For 3 Years

(NBCNews) May 18, 2016 - The cancer drug that former president Jimmy Carter says made his melanoma seemingly disappear has helped about 40 percent of similar patients survive for as long as three years, oncologists said Wednesday.
read article 



Merck, Bristol Drugs Show Longer Survival for Deadly Cancers

(Reuters) May 18, 2016 - Two new drugs that help the immune system fight some of the deadliest cancers are helping patients live years longer than older treatments, according to clinical trial results that should further boost confidence in this approach to oncology.
read article 



German Merck, Pfizer Immunotherapy Shows Promise In Rare Skin Cancer

(Reuters) May 18, 2016 - Germany's Merck KGaA on Wednesday reported encouraging interim data against a rare and aggressive form of skin cancer from a mid-stage trial of its experimental drug that helps the immune system attack tumors.
read article